Leash Biosciences Raises $9.3M for AI-Driven Drug Discovery Model

Leash Biosciences Raises $9.3M in Seed Funding

Key Highlights:

• Seed Funding: Leash Biosciences, an AI/ML-native biotechnology company, secured $9.3 million in seed funding.
• Investors: Springtide Ventures led the round, with participation from MetaPlanet, Top Harvest Capital, Mitsui Global Investment, MFV Partners, and Recursion co-founders Chris Gibson and Blake Borgeson.
• Medicinal Chemistry Advancement: Funds will support the development of a machine learning model for predicting small molecule drug candidates for any protein.

Leash Biosciences' Target Market

• Biotechnology and Pharmaceutical Companies: Potential customers include companies in the biotech and pharmaceutical sectors seeking innovative solutions for drug discovery and development.
• Research Institutions: Collaborations with academic and research institutions focused on advancing medicinal chemistry and drug discovery.
• Investors and Partners: Partnerships with venture capital firms, strategic investors, and technology companies interested in AI/ML-driven biotechnology.

What Leash Biosciences Needs to Buy

• Data and Computational Resources: Access to chemical and biological datasets, as well as computational resources for machine learning model development.
• Research and Development Collaboration: Partnerships with academic and research institutions for joint research projects and data sharing.
• Marketing and Business Development Support: Services to help promote Leash Biosciences' capabilities and establish partnerships with potential customers and investors.